目的 探討骨風寧膠囊聯(lián)合吲哚美辛治療強直性脊柱炎的臨床效果。方法 選取2019年7月—2020年7月在鄭州大學(xué)第一附屬醫(yī)院治療的230例強直性脊柱炎患者為研究對象，隨機分為對照組（115例）和治療組（115例）。對照組口服吲哚美辛腸溶片，50 mg/次，2次/d；治療組在對照組的基礎(chǔ)上口服骨風寧膠囊，3粒/次，3次/d；兩組連續(xù)治療15 d。觀察兩組患者臨床療效，比較治療前后兩組臨床癥狀改善時間、Bath強直脊柱炎功能指數(shù)（BASFI）、Bath強直脊柱炎疾病活動指數(shù)（BASDAI）、強直性脊柱炎計量學(xué)指數(shù)（BASMI）、血清白細胞介素-2（IL-2）、IL-4、腫瘤壞死因子-α（TNF-α）和干擾素-γ（IFN-γ）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床總有效率為98.26%，明顯高于對照組的86.09%（P<0.05）。治療后，治療組腰痛、晨僵、背痛、關(guān)節(jié)痛改善時間明顯短于對照組（P<0.05）。治療后，兩組患者BASFI、BASDAI、BASMI評分明顯低于治療前（P<0.05），且治療組顯著低于對照組（P<0.05）。治療后，兩組患者IL-2、IL-4、TNF-α、IFN-γ水平明顯低于治療前（P<0.05）；且治療組患者顯著低于對照組（P<0.05）。治療組患者藥物不良反應(yīng)總發(fā)生率明顯低于對照組（P<0.05）。結(jié)論 骨風寧膠囊聯(lián)合吲哚美辛腸溶片治療能夠有效的緩解強直性脊柱炎患者主要癥狀，降低BASFI、BASDAI、BASMI評分和炎癥因子水平，療效顯著，安全可靠。

Objective To investigate the clinical study of Gufengning Capsules combined with indomethacin in treatment of ankylosing spondylitis. Methods Patients (230 cases) with ankylosing spondylitis in the First Affiliated Hospital of Zhengzhou University from July 2019 to July 2020 were randomly divided into control (115 cases) and treatment (115 cases) groups. Patients in the control group were po administered with Indometacin Enteric-coated Tablets, 50 mg/time, twice daily. Patients in the treatment group were po administered with Gufengning Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, the BASFI, BASDAI, and BASMI scores, the levels of serum inflammatory factors, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 98.26%, which was significantly higher than 86.09% in the control group (P<0.05). After treatment, the improvement time of low back pain, morning stiffness, back pain, and joint pain in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the scores of BASFI, BASDAI, and BASMI in the two groups were significantly lower (P<0.05), and which in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the levels of IL-2, IL-4, TNF- α, and IFN- γ in the two groups were significantly lower (P<0.05), and which in the treatment group were significantly lower than those in the control group. The total incidence of adverse drug reactions in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Gufengning Capsules combined with Indometacin Enteric-coated Tablets can effectively relieve the main symptoms of patients with ankylosing spondylitis, reduce the scores of BASFI, BASDAI, BASMI and inflammatory factors.

R977

河南省醫(yī)學(xué)科技攻關(guān)計劃（聯(lián)合共建）（LHGJ20190253）